arrow
M

Mayu Yunokawa

Department of Gynecology
H指数:34
被引数:5,999

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of lymphovascular space invasion on lymph node metastasis in low-grade endometrial cancer with shallow myometrial invasion and negative imaging

低级别子宫内膜癌中淋巴血管间隙侵犯对浅肌层浸润且影像学阴性患者的淋巴结转移的影响

2026-08-210
PRE
Lenvatinib Plus Pembrolizumab in Participants With Advanced or Recurrent Endometrial Cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(Neo)Adjuvant Therapy Outcomes

Lenvatinib联合Pembrolizumab在晚期或复发性子宫内膜癌患者中的应用:Study 309/KEYNOTE-775和ENGOT-en9/LEAP-001术后(新辅助)治疗结局

2026-04-120
PRE
Prevalence and clinicopathologic features of mismatch repair–deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational study

日本50岁以下患者中错配修复缺陷型子宫内膜癌的患病率及临床病理特征:一项单中心前瞻性观察研究

2026-04-090
PRE
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial

在预后不良的卵巢癌中,添加免疫检查点抑制剂atezolizumab到一线化疗对无进展生存期的影响:IMagyn050试验的一项回顾性分析

2025-06-010
OAAI
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors

自动化和去中心化的血浆游离DNA基因组分析,用于识别晚期实体瘤中的可靶向突变和耐药性改变

2025-05-050
OA
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2024-01-0155
OAAI
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

研究309中的东亚亚组分析/主旨775: 来伐替尼联合帕博利珠单抗与医生选择化疗治疗晚期或复发性子宫内膜癌患者的比较

2024-01-016
OAAI
Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cance
2023-12-010
PRE
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
2023-02-0112
OAAI
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
2023-01-192
OAAI
Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer
2022-01-0710
OAAI